Piramal Pharma Solutions (PPS) has entered an agreement to acquire Hemmo Pharmaceuticals Pvt Ltd. for an upfront consideration of $106 million plus milestone payments.   The acquisition marks PPS’ foray into the development and manufacture of peptide APIs. Hemmo, a pure-play synthetic peptide API manufacturer in the global marketplace, gives PPS access to the growing peptide API market and enhances its integrated CDMO service offering globally.   Hemmo is one of India’s largest manufacturers...